Table 3. Experimental pIC50 Values of the Compounds Included in the Prospective Study by Combining the Nine Best Candidates Selected from Both QE + R3 and log P + HB Pharmacophoresa.
| compound | hsEH | msEH | rsEH |
|---|---|---|---|
| log P + HB-Selected Compounds | |||
| Z211852480 | 6.9 | 6.2 | 6.3 |
| AK-968/41927527 | 9.4 | 8.9 | 9.4 |
| Z211761694 | 6.7 | 6.3 | 6.7 |
| Z339843288 | 8.9 | 8.9 | 9.0 |
| Z416144030 | 7.8 | 6.7 | 7.7 |
| Z436130862 | 9.1 | 9.0 | 9.0 |
| Z1499294365 | 7.7 | 7.1 | 7.4 |
| Z237696036 | 6.7 | 5.3 | 6.4 |
| Z353003074 | 8.2 | 8.0 | 8.3 |
| QE + R3-Selected Compounds | |||
| Z29532165 | 6.3 | 6.4 | 7.4 |
| AK-968/15603026 | 6.9 | 6.5 | 7.4 |
| AO-476/43362680 | 5.4 | 4.6 | 4.6 |
| AK-968/40204236 | 6.8 | 5.8 | 6.5 |
| Z23294293 | 7.0 | 6.2 | 7.4 |
| Z44611499 | 8.2 | 6.9 | 7.7 |
| Z1033382608 | 6.3 | 5.5 | 6.4 |
| Z339670416 | 7.0 | 5.8 | 6.3 |
| Z65159029 | 5.3 | 4.7 | 5.7 |
a
Compounds with an inhibitory potency against hsEH lower than 20 nM are highlighted in bold.